agilon health inc (NYSE:AGL)
Income Statement
Mar-2022 | Dec-2021 | Sep-2021 | Jun-2021 | ||
---|---|---|---|---|---|
Revenue | |||||
Revenue |
2 074
+13%
|
1 834
+34%
|
1 371
+12%
|
1 225
N/A
|
|
Gross Profit | |||||
Cost of Revenue |
(1 854)
|
(1 648)
|
(1 217)
|
(1 064)
|
|
Gross Profit |
220
+19%
|
186
+21%
|
154
-5%
|
161
N/A
|
|
Operating Income | |||||
Operating Expenses |
(603)
|
(580)
|
(500)
|
(481)
|
|
Selling, General & Administrative |
(588)
|
(565)
|
(489)
|
(471)
|
|
Depreciation & Amortization |
(14)
|
(15)
|
(11)
|
(10)
|
|
Operating Income |
383
+3%
|
370
+15%
|
322
+16%
|
276
N/A
|
|
Pre-Tax Income | |||||
Interest Income Expense |
4
|
0
|
(1)
|
(3)
|
|
Total Other Income |
5
|
7
|
(1)
|
(2)
|
|
Pre-Tax Income |
392
+4%
|
377
+18%
|
320
+18%
|
271
N/A
|
|
Net Income | |||||
Tax Provision |
(1)
|
(1)
|
(1)
|
(0)
|
|
Income from Continuing Operations |
392
|
378
|
321
|
271
|
|
Income to Minority Interest |
0
|
0
|
0
|
0
|
|
Net Income (Common) |
393
+4%
|
376
+18%
|
320
+18%
|
272
N/A
|
Balance Sheet
Mar-2022 | Dec-2021 | Sep-2021 | Jun-2021 | Mar-2021 | ||
---|---|---|---|---|---|---|
Assets | ||||||
Cash & Cash Equivalents |
1 022
|
1 040
|
1 082
|
1 109
|
105
|
|
Cash Equivalents |
1 022
|
1 040
|
1 082
|
1 109
|
105
|
|
Total Receivables |
572
|
293
|
343
|
338
|
289
|
|
Accounts Receivables |
572
|
293
|
343
|
338
|
289
|
|
Other Receivables |
0
|
0
|
0
|
0
|
0
|
|
Other Current Assets |
34
|
34
|
29
|
32
|
24
|
|
Total Current Assets |
1 628
|
1 367
|
1 453
|
1 480
|
418
|
|
PP&E Net |
25
|
21
|
10
|
14
|
14
|
|
Intangible Assets |
54
|
55
|
58
|
59
|
62
|
|
Long-Term Investments |
11
|
0
|
0
|
0
|
0
|
|
Other Long-Term Assets |
96
|
101
|
122
|
108
|
39
|
|
Other Assets |
42
|
42
|
42
|
42
|
42
|
|
Total Assets |
1 855
+17%
|
1 586
-6%
|
1 685
-1%
|
1 702
+196%
|
574
N/A
|
|
Liabilities | ||||||
Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
|
Current Portion of Long-Term Debt |
5
|
5
|
5
|
4
|
0
|
|
Other Current Liabilities |
472
|
239
|
288
|
301
|
277
|
|
Total Current Liabilities |
610
|
357
|
423
|
412
|
372
|
|
Long-Term Debt |
42
|
43
|
45
|
46
|
99
|
|
Minority Interest |
0
|
0
|
0
|
0
|
0
|
|
Other Liabilities |
91
|
94
|
90
|
93
|
91
|
|
Total Liabilities |
743
+50%
|
494
-11%
|
557
+1%
|
551
-2%
|
563
N/A
|
|
Equity | ||||||
Common Stock |
4
|
4
|
4
|
4
|
312
|
|
Retained Earnings |
956
|
958
|
901
|
865
|
566
|
|
Additional Paid In Capital |
2 064
|
2 046
|
2 025
|
2 012
|
266
|
|
Total Equity |
1 112
+2%
|
1 092
-3%
|
1 128
-2%
|
1 150
+10 081%
|
11
N/A
|
|
Total Liabilities & Equity |
1 855
+17%
|
1 586
-6%
|
1 685
-1%
|
1 702
+196%
|
574
N/A
|
|
Shares Outstanding | ||||||
Common Shares Outstanding |
406M
|
400M
|
394M
|
391M
|
384M
|
Cash Flow Statement
Mar-2022 | Dec-2021 | Sep-2021 | Jun-2021 | ||
---|---|---|---|---|---|
Operating Cash Flow | |||||
Net Income |
423
|
443
|
386
|
338
|
|
Depreciation & Amortization |
15
|
4
|
1
|
0
|
|
Change in Deffered Taxes |
0
|
3
|
0
|
0
|
|
Other Non-Cash Items |
300
|
297
|
282
|
274
|
|
Cash Taxes Paid |
5
|
2
|
2
|
2
|
|
Cash Interest Paid |
4
|
(1)
|
(2)
|
(1)
|
|
Change in Working Capital |
119
|
74
|
67
|
72
|
|
Cash from Operating Activities |
212
+13%
|
188
+35%
|
139
+20%
|
116
N/A
|
|
Investing Cash Flow | |||||
Capital Expenditures |
23
|
15
|
12
|
6
|
|
Other Items |
86
|
76
|
77
|
73
|
|
Cash from Investing Activities |
108
+18%
|
92
+3%
|
89
+13%
|
79
N/A
|
|
Financing Cash Flow | |||||
Net Issuance of Common Stock |
1 204
|
1 161
|
1 145
|
1 138
|
|
Net Issuance of Debt |
(10)
|
22
|
21
|
20
|
|
Other |
0
|
15
|
10
|
10
|
|
Cash from Financing Activities |
1 138
+1%
|
1 129
+1%
|
1 119
+1%
|
1 112
N/A
|
|
Change in Cash | |||||
Net Change in Cash |
1 458
+4%
|
1 409
+5%
|
1 347
+3%
|
1 306
N/A
|
|
Free Cash Flow | |||||
Free Cash Flow |
235
+16%
|
203
+35%
|
151
+24%
|
122
N/A
|